Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: JL Sorry to hear about your covid.
Very glad you made it through! Many I know were not so fortunate.
The Volume seems to finally be coming back to this security.
Let's see if it is sustained long enough to make some of the short interest decrease.
Very little of it is me. :)
Do take care!
Wow, I go away for a short time and you all couldn't hold up the stock for us? :)
JL: We no longer have the volume
The shorts can kick us around because between you, me and the other 6 people on this board we cannot prop up this company. :)
The volume/interest has decreased greatly in the last month.
Some interesteing tidbits in the 10-K
Bionano Genomics to Present at the Cowen 41st Annual Health Care Conference
GLOBENEWSWIRE 3/2/2021
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.(BNGO) announced today that company management will present virtually at the Cowen 41st Annual Health Care Conference. Erik Holmlin, PhD, Bionano’s Chief Executive Officer, is scheduled to present on Thursday, March 4, 2021 at 2:10 pm EST.
A live webcast of the presentation will be available to view on the Events page in the Investors section of Bionano’s website at https://ir.bionanogenomics.com/ and will be archived on Bionano’s website for 30 days following the event.
About Bionano Genomics(BNGO)
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s capabilities in comparison to and in conjunction with other genome analysis technologies, including in the comprehensive analysis of cancer genomes; the potential for Saphyr to reduce or eliminate sequential and confirmatory assays and expedite patient treatment; our expectations regarding the adoption of Saphyr as a clinical tool to replace traditional standard of care cytogenomic testing methods; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.(BNGO)
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
Image: Primary Logo
Source: Bionano Genomics(BNGO)
Vanguard Adding 1,451,519
Filing date 2021-03-01 VEXMX - Vanguard Extended Market Index Fund Investor Shares 1,451,519
Filing date 2021-02-24 13F/A Bank Julius Baer & Co. Ltd, Zurich Shares 850,000
Many new institutional opening brand new positions in last month (green) compared to closing positions (red)
HEre's a tidy list...
https://fintel.io/so/us/bngo
Bionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer
https://ir.bionanogenomics.com/single-news-releases/?storyid=6252306995556583
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) --
Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2021 Advances in Genome Biology and Technology (AGBT) meeting will feature presentations from scientists at leading research institutes and hospitals including Boston Children’s Hospital, Harvard Medical School, Tel Aviv University and the company describing their work with the Saphyr System for optical genome mapping (OGM) in psychiatric disorders and cancer. AGBT will be held virtually at https://www.agbt.org/ March 1-3. Bionano’s optical genome mapping technology will be discussed in poster presentations and plenary talks on AGBT’s main agenda. Additionally, Bionano will host a live interview with Bionano CEO Dr. Erik Holmlin and CMO Dr. Alka Chaubey conducted by Theral Timpson, Host, Producer and Co-Founder of Mendelspod as part of the official conference program. The recording of the interview will be released on Thursday, March 4 as a regular episode of Mendelspod, the leading podcast covering the genomics industry.
Below is a list of activities at AGBT 2021 featuring the use of Bionano’s optical genome mapping technology:
Plenary Talk – Session I
Monday, March 1 – 10:30A-10:50A (EST)
Research in rare pediatric psychiatric disorders (and more)
Dr. Catherine Brownstein, Assistant Professor at Boston Children’s Hospital and Harvard Medical School
Poster Presentation – Cancer Omics
Monday, March 1 – 3:45P-5:45P (EST)
Deep structural variance landscape mapping of renal tissue-renal cell carcinoma pairs originating from the same kidney
Dr. Tulpova Zuzana, Tel Aviv University
Poster Presentation – Technology Development
Tuesday, March 2 – 3:30P-5:30P (EST)
Identifying Polymorphic Variants at Complex Regions Using Optical Genome Mapping
Dr. Joyce Lee, Bionano Genomics
Tuesday, March 2 – 5:30P-6:30P (EST)
Hear About the Future of Genomic Analysis with Bionano’s CEO and CMO
Live interview of Dr. Erik Holmlin, CEO and Dr. Alka Chaubey, CMO of Bionano Genomics by Theral Timpson, Host, Producer and Co-Founder of Mendelspod
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release and Bionano’s participation in the live interview conducted by Theral Timpson. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
News: Bionano's Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed
Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication in Science of a study by the Human Genome Structural Variation Consortium (HGSVC) that used a combination of advanced sequencing and optical genome mapping (OGM) with Saphyr to assemble with high resolution and structural accuracy 64 haplotype-resolved human genomes from 32 individuals representing 25 different populations. The peer-reviewed publication, which previously appeared on the pre-print server bioRxiv, builds on the original Human Genome Project to better capture genetic diversity by cataloging both single nucleotide variations (SNVs) and structural variations (SVs) from each individual reference-quality genome assembly compared to the standard human genome reference. The resulting assemblies and catalog of SNVs and SVs can serve as a diversity panel that researchers and clinicians can use to accelerate the discovery of new therapeutic targets and pathogenic genetic variations by making it easier and faster to filter out variation that is representative of population diversity. They further enable population-specific studies on genetic predispositions to human diseases as well as the potential discovery of more complex forms of genetic variation.
Regarding OGM’s contribution to the variants that were identified, OGM uniquely made 5,590 large SV calls missed by long-read based genome assemblies, corresponding to 1,175 unique SV loci. Many of these large SVs consisted of more complex rearrangements or overlap with large repetitive areas called segmental duplications which are associated with developmental delay and adult neuropsychiatric disease, highlighting the importance of OGM in genome structure analysis.
“Bionano is proud that OGM has made such a significant contribution to this impressive work,” commented Erik Holmlin, PhD, CEO of Bionano Genomics. “OGM complements even the most advanced sequencing technology and plays an essential role in identifying large structural variants, including those in the most complex parts of the genome, as the authors of this study pointed out. We believe the study by the HGSCV underscores the point that if you are performing a genome analysis without getting an accurate structural picture, you are not doing a deep enough analysis. It further illustrates that when it comes to looking for large SVs, OGM with Saphyr has unmatched sensitivity.”
The work by the HGSVC is an extension of the human genome project. In 2001, the International Human Genome Sequencing Consortium announced the first draft of the human genome reference sequence. This reference does not represent a single individual but instead is a composite of humans that could not accurately capture the complexity of human genetic variation. Building that reference, scientists have carried out many sequencing projects over the last 20 years to identify and catalog genetic differences between an individual and the reference genome. Those projects usually focused on small single base changes and missed SVs, which are widely viewed to be more likely than smaller genetic differences to interfere with gene function. This article in Science has been published by an international research team and represent a significant advance in the tools available for scientists and clinicians who want to discover new biology en route to new medicines and diagnostics that can improve outcomes for patients.
The publication is available at https://science.sciencemag.org/lookup/doi/10.1126/science.abf7117
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential for OGM with Saphyr to improve outcomes for patients by enabling the discovery of new medicines and diagnostics; our beliefs regarding the potential benefits of Bionano’s Saphyr technology; the significance of large SVs in genetic research; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
???Government rushes virus gene-mapping as mutations spread
The U.S. is scrambling to expand DNA mapping of coronavirus samples taken from patients to identify potentially deadlier mutations that are starting to spread around the country
By RICARDO ALONSO-ZALDIVAR Associated Press
February 17, 2021, 2:35 PM
https://abcnews.go.com/Health/wireStory/covid-19-bill-scale-ability-spot-virus-mutations-75938830
Rochelle Walensky
The Associated Presse
WASHINGTON -- The U.S. is scrambling to expand DNA mapping of coronavirus samples taken from patients to identify potentially deadlier mutations that are starting to spread around the country.
On Wednesday, the White House announced a scaled up push by the Centers for Disease Control and Prevention, and by a U.S. Army biodefense institute. But the more significant action is on Capitol Hill, where a House bill headed for floor debate would provide $1.75 billion for genomic sequencing.
“I don’t think this is going to be a light switch; I think its going to be a dial,” CDC head Dr. Rochelle Walensky told reporters, as she described the effort.
The U.S. now maps only the genetic makeup of a minuscule fraction of positive virus samples, a situation some experts liken to flying blind. It means the true domestic spread of problematic mutations first identified in the United Kingdom and South Africa remains a matter of guesswork.
Such ignorance could prove costly. One worry is that more transmissible forms such as the UK variant could move faster than the nation's ability to get the vaccine into Americans' arms.
“You've got a small number of academic and public health labs that have been basically doing the genomic surveillance,” said David O'Connor, an AIDS researcher at the University of Wisconsin. “But there is no national coherence to the strategy.”
The CDC is trying to shepherd those efforts and align them with the government's own expanded commitment. Officials said Wednesday the administration will spend $200 million for the CDC to increase genomic sequencing to about 25,000 samples a week, or triple the current level.
On a parallel track, a U.S. Army biodefense institute will increase coronavirus gene mapping to 10,000 samples a week by the end of the month, up from about 4,000.
Provisions of President Joe Biden's COVID relief bill would take the hunt to another level.
Besides a $1.75 billion budget for gene mapping, House legislation that cleared the Energy and Commerce Committee last week calls for the CDC to organize a national network to use the technology to track the spread of mutations and guide public health countermeasures.
In the Senate, Wisconsin Democrat Tammy Baldwin has introduced a bill that would provide $2 billion. Baldwin says the U.S. should be analyzing at least 15% of positive virus samples. That might not sound like much, but the current rate is believed to be 0.3% to 0.5%. Analyzing 15% of positive samples would expand surveillance by at least 30 times.
Genomic sequencing essentially involves mapping the DNA of an organism, the key to its unique features. It's done by high-tech machines that can cost from several hundred thousand dollars to $1 million or more. Technicians trained to run the machines and computing capacity to support the whole process add to costs.
In the case of the UK variant first detected in England, the changes in the virus allowed it to spread more easily and are also believed to cause deadlier COVID-19 disease. Walensky said it has already been identified in more than 40 states.
“Genomic sequencing testing is how we will spot variants early before they spread,” said White House COVID response coordinator Jeff Zients.
Sequencing 0.3% to 0.5% of virus samples, as the U.S. is now doing, “just doesn’t give us the ability to detect strains as they develop and become dominant,” said Dr. Phil Febbo, chief medical officer for Illumina, a San Diego-based company that develops genomic sequencing technologies.
The Biden administration has to “set a very clear goal,” he added. “What's the hill that we are going to charge?”
“We need that data. Otherwise, in some ways, we're flying blind,” said Esther Krofah, who directs the FasterCures initiative of the Milken Institute.
Even more worrisome than the UK variant is a strain first detected in South Africa that scientists suspect may diminish the protective effect of some of the coronavirus vaccines. That variant has also been identified in the U.S. in a limited number of cases.
At the University of Wisconsin, AIDS scientist O'Connor said the CDC's new goal of gene-mapping 25,000 samples a week works out to about 5% of U.S. cases, still below the level of surveillance in the United Kingdom. He and his colleagues started sequencing coronavirus samples from the Madison area “because that's where we live.”
His colleague, virology expert Thomas Friedrich, said a national effort will require more than money to purchase new genomic sequencing machines. The CDC will have to set standards for state health officials and academic research institutions to fully share the information they glean from analyzing virus samples. Currently, there's a hodgepodge of state regulations and practices, and some of them restrict access to key details.
“We need to look at this as a Manhattan Project or an Apollo program,” said Friedrich, invoking the government-led scientific endeavors that developed the atomic bomb and landed men on the moon.
The United Kingdom was able to identify its variant because the national health system there has a coordinated gene mapping program that aims to sequence about 10% of samples, he added. Since that happened, there's been greater urgency on this side of the Atlantic Ocean.
“The utility of doing this may not have been as apparent to as many people until these variants started popping up,” Friedrich said.
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?
https://www.nasdaq.com/articles/bionano-bngo-to-report-q4-earnings%3A-whats-in-the-offing-2021-02-22
CONTRIBUTOR
Zacks Equity Research Zacks
PUBLISHED
FEB 22, 2021 10:09AM EST
We expect Bionano Genomics, Inc. BNGO to beat expectations when it reports fourth-quarter and full-year 2020 results.
The stock has skyrocketed1156.4% in the past year compared with the industry's growth of 13.9%
The company missed expectations by 33.33% in the last reported quarter. Over the trailing four quarters, it missed earnings estimates on two occasions while matched in one. The four-quarter average negative earnings surprise is 23.23%.
Let us see how things have shaped up prior to this announcement.
Factors in Focus
Bionano is a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.
The company generates product revenues from the sale of its instruments and consumables. It currently sells its products for research-use-only applications. Consumable revenues consist of sales of complete assays, which are developed internally, along with sales of kits that contain all elements necessary to run tests.The company also generates service revenues from the sale of diagnostic testing services for those with autism spectrum disorder and other neuro developmental disabilities through its wholly-owned subsidiary, Lineagen. Other revenues consist of warranty and other service-based revenues.
Total revenues were $2.2 million in the previous quarter, down 33.7% from the year-ago quarter due to a change in the mix of revenues between instrument sales and our reagent rental program.
Operating expenses grew 46% in the last reported quarter due to increased legal and accounting fees to support business operations and the company’s international presence, including approximately $1.5 million in transaction costs associated with the Lineagen acquisition and an increase in wage expenses as a result of the addition of employees from the Lineagen acquisition. Increased headcount in the company’s global sales and marketing teams and back-office support teams to assist with the growth of its worldwide product distribution also led to the increase. Expenses are most likely to have been higher in the quarter under review.
In December 2020, Bionano achieved a key milestone for the throughput of its Saphyr System. With the release of a software update for the Saphyr Instrument, part of its system for optical genome mapping, the system is now capable of imaging up to 96 human genomes per week to a depth of coverage of 100x, or 4,992 samples per year. Saphyr Assure is designed to monitor Saphyr's health and, once enabled, can alert Bionano support of potential issues and allow itto recommend preventative services. Also, with a growing installed base of customers looking to put Saphyr into production use, Saphyr Assure will allow Bionano to work in conjunction with customers to optimize Saphyr uptime in these time-sensitive settings. We expect an update on this in the fourth quarter.
In January 2021,Bionano released version 1.2 of its Compute On Demand (COD) cloud compute solution, which significantly reduces the cost and time to analyze structural variants (SVs) in a human genome. This update is part of the company’scontinuous efforts to decrease time to results while reducing per sample costs to make Saphyr data available toevery clinician and researcher. We expect an update on this in the fourth quarter.
Earnings Whispers
Our proven model predicts an earnings beat for Bionano in the soon-to-be-reported quarter.The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Bionano’s Earnings ESP is + 9.09% as the Most Accurate Estimate of a loss of 5 cents is pegged narrower than the Zacks Consensus Estimate of a loss of 6 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Bionanohas a Zacks Rank #3.You can see the complete list of today’s Zacks #1 Rank stocks here.
JL: Good shopping day yesterday.
As long as you didn't look at your main portfolio. :)
The FED will do nothing that will interfere with keeping the part of America that has investments OK even know some inflation fears. Do not mess with the markets. They have enough to worry about.
They will lay low.
RE: 70's: Coming out of high school in the late 70's inflation, my first CD had an interest rate of 16%! I do not see us getting there any time soon :)
Meanwhile, Getting the word out about BNGO can not come fast enough. :)
I agree with you about not only the health, but the economic consequences.
What I think is wonderful is the fact that Patients will not have to fight Insurance companies because of the cost of this testing. This test has a cost less than my last round of blood tests!
Affordable testing that can prevent future costs. Win win.
Article yeaterday: BNGO Stock: What to Know as Bionano Genomics Drops 15% Today
BNGO stock may be falling, but recent company news offers reason for optimism
https://investorplace.com/2021/02/bngo-stock-what-to-know-as-bionano-genomics-drops-15-today/
By Sarah Smith, InvestorPlace Web Content Producer Feb 23, 2021, 2:24 pm EST
Investors are feeling the heat with popular Bionano Genomics (NASDAQ:BNGO) today. Despite no real news, shares are down more than 15% in intraday trading. So what should you know now? And what could be behind the slump in BNGO stock?
Bionano Genomics is a a popular biotech company that has rallied throughout 2021. Despite this, BNGO stock is down 15% today.
Recent press releases speak to its growth and its opportunities in genetic research.
Yesterday, its Lineagen division announced a new publication that should ultimately improve its diagnostic abilities.
To start, investors should be sure to understand the company. Bionano Genomics, as its name implies, is a genome analysis business. It provides a variety of solutions for genetic research and testing, and also provides testing for patients with Autism Spectrum Disorder (ASD). Perhaps because of growing interest in gene-editing and testing thanks to Ark Invest, its Saphyr system has been captivating investors.
In fact, earlier in February, positive results from that Saphyr system were a driver of serious gains. Add in new listing compliance, a fireside chat and a pilot program in Canada, and the BNGO stock story looked pretty appealing.
Yesterday, that story got even stronger. The company said its Lineagen team had published a new study, and that the study describes the first genome-wide model to “asses and score nearly all protein-coding genes based on their likelihood to cause central nervous system (CNS) disease.” In other words, Lineagen now has new information to help its clinical interpretation. It can aid genetic counselors, improve diagnostics and help give more precise health info to patients. And perhaps even more importantly, Bionano can take the Lineagen study results and integrate them into the Saphyr system.
Talk about a win-win for science and for BNGO stock.
Why BNGO Stock Is Falling Today
With all that in mind, investors may be wondering why BNGO stock is falling today. However, it is important to recognize that seemingly the entire market is suffering. Top names like Tesla (NASDAQ:TSLA) are in the red, and other popular equities on Wall Street are down. This could mean that the high-flying stock is just moving in sympathy with the market. It also could mean that with a sense of panic influencing trading, investors are apprehensive about a riskier company. Although Bionano has been earning praise, biotech stocks in general represent uncertainty.
Looking to the future though, there is no reason to panic without new information about Bionano Genomics. In fact, a few catalysts should start to boost biotech stocks again. SoftBank (OTCMKTS:SFTBY) announced today that it plans to invest billions in biotech stocks as part of its plan to expand its reach in healthcare. Many retail investors could follow in its footsteps.
Keep calm, and keep BNGO stock on your radar here.
On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in this article.
timetravelerdos:
Perhaps we are all impatient, but look what this stock has done over the past 2 months.
This is a long term investment. The only reason I am a bit impatient is the fact that I liked the company so much it, and it has risen so much, I am overweight it in my portfolio. The stock price rising further will only make me more nervous about it's abilitites to make good on what i think is possible for it to acheive. I want to see all the posibilities immediately implemented in healthcare. The faster they acheive their goals, the more lives can be helped. Win win. :)
Do take care~!
VH
JL: Great product, can they sell it?
You and I agree that the possibilities are almost endless for uses of this technology. I was taken immediatly with my initial research.
Earnings next month have to be stellar as this company's stock price just eats news without flinching.
I am curious, at a time like this, they are looking for a new head of marketing unless because of all the planned expansion and new hiring and new space, Head of Marketing becomes a stand alone position. They seem to be hiring in many areas including regional business manager in Germany.
16,000 sq' of a beautiful new office space needed sounds nice but, why warehouse in office buildings?
I would rather see a Christmas tree than stop lights on my screen today but, whole market tanks a bit today. Thankfully my screen just turned green after hours except for PLTR and BNGO
Time will tell if I am a genius or a true idiot, I bought more BNGOW Warrents today in the low 7's.
Do take care and be safe!
VH
Leverage the Power of Genetics Tech With Bionano Genomics
As BNGO stock climbs, let's not lose sight of the life-changing potential of gene therapy
https://investorplace.com/2021/02/leverage-the-power-of-genetics-tech-with-bngo-stock/
By David Moadel, InvestorPlace Contributor Feb 22, 2021, 2:02 pm EST
Biotechnology companies can be broad in their medical ambitions, or they can be specific. Interestingly, Bionano Genomics (NASDAQ:BNGO) is both a specialist and a generalist, and the company’s Saphyr System addresses multiple important medical issues. This duality is what makes BNGO stock so unique as an investment.
I’ll admit, the technical aspects of BNGO stock are also quite interesting. We’ll get into more detail about that, but suffice it to say that shareholders have enjoyed tremendous gains in 2021.
Even among biotech stocks, which are known for making outsized moves, BNGO stock has brought seemingly excessive pain to the short sellers. Yet, the lofty share price might be justified if we truly believe in the science that Bionano is pursuing.
It’s an age-old question: does it make sense to buy a stock after a huge run-up? There’s no universal answer to that question, so we’ll have to weigh BNGO stock’s price action against the value proposition of the company itself.
A Closer Look at BNGO Stock
It wasn’t very long ago when Bionano shareholders were experiencing what might be called a rough patch. Indeed, there was a time in December when BNGO stock was trading at just 50 cents.
That was problematic, as the Nasdaq has been known to sometimes de-list stocks if their prices remain below $1 for too long.
Any de-listing fears were put to rest in late December, however. The bull train left the station on Dec. 29, when BNGO stock suddenly popped above the crucial $1 level.
And then, it just kept going. The BNGO share price reached $7 on Jan. 4, followed by $25 on Jan. 25. On Feb. 15, BNGO stock touched a dazzling 52-week high of $15.69.
Incidentally, in January the Nasdaq Exchange confirmed BNGO stock’s compliance with the exchange’s listing requirements as the stock had traded at or above $1 for 10 consecutive business days.
Sensitive and Specific
Whether all of the foregoing is good or bad news depends on one’s perspective. Value-focused investors might balk at the idea of buying a stock after such a steep run-up.
But then, at least the de-listing fears have been quelled and if the trend is truly your friend, then the price action in BNGO stock appears to be quite bull-friendly.
On top of that, it’s evident that Bionano Genomics is a true innovator with a groundbreaking medical tech platform.
As the company describes it, the Saphyr System is “a genome imaging tool for high-speed, high-throughput structural variant detection and analysis with exceptional sensitivity and specificity.”
How sensitive and specific is it? According to the company, the Saphyr System “reveals structural variants (>500 bp), at sensitivities as high as 99%, with false positive rates below 2%.”
Moreover, the Saphyr System has a surprisingly wide range of medical applications. These include undiagnosed genetic disorders, hematologic malignancies, gene discovery and therapy, solid tumor research, reference gene assembly and more.
Potential Breakthrough in Oncology
Encouragingly for patients and other stakeholders, Bionano Genomics recently announced the publication of a method for using optical genome mapping to identify cancer-driving structural variants in a variety of solid tumor samples.
The relevant clinical study was led by Dr. James Broach of the Penn State Institute for Personalized Medicine. In the study, the Saphyr System characterized structural variations in 20 solid tumor samples from cancer patients.
There were a number of key findings:
The Saphyr System can consistently isolate ultra-high molecular weight DNA from solid tumors.
BioNano’s software can identify the cancer-specific variants in these tumors. This is true even when the variants are present at low abundance in highly complex tumors.
In every sample, the optical genome mapping methodology detected cancer-specific “variants affecting important cancer genes.”
This could mark a breakthrough moment for the oncology field, and shareholders should keep an eye out for further developments.
The Bottom Line on BNGO Stock
It’s true that BNGO stock has posted strong gains lately, and valuation may be a legitimate concern. However, shares could still have room to run.
The Saphyr System’s breakthrough technology is clearing pathways to progress in the oncology field. Thus, all stakeholders — including Bionano’s investors — should remain optimistic.
On the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Bionano Publishes Method for Identifying Genes Likely to Cause Neurological Diseases Based on a Model Developed by Lineagen to Improve Interpretation of Variants of Unknown SignificanceProprietary scoring algorithm may help identify novel genes for nervous system disorders; applications include patient testing and eventually discovery research with Saphyr
GLOBENEWSWIRE 8:00 AM ET 2/22/2021
https://ir.bionanogenomics.com/single-news-releases/?storyid=7801927834883852
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.(BNGO) announced the publication of a study by its Lineagen team that describes the first genome-wide model to assess and score nearly all protein-coding genes based on their likelihood to cause central nervous system (CNS) disease. The resulting list of high scoring genes enhances Lineagen’s clinical interpretation capabilities allowing their genetic counsellors to better interpret variants of unknown significance (VUS), which can improve diagnostic abilities and provide for more precise counseling to patients and families. The gene scoring model can also be integrated into Bionano’s analysis software for Saphyr data, allowing scientists and clinicians to quickly identify and filter structural variants based on their increased risk of causing CNS diseases.
The model, called the Neurogenic Systematic Correlation of Omics-Related Evidence, or NeuroSCORE, combines data from five public and proprietary genomics databases containing evidence on whether genes are highly expressed in the adult or developing human brain, have high rates of new genetic variation in people with CNS diseases and have few variants in individuals without neurological disorders. Armed with NeuroSCORE, scientists could discover novel genes not previously associated with CNS diseases, potentially enabling clinicians to more accurately diagnose patients with previously uncharacterized neurodevelopmental disease. These advances may make it possible to better study the complex molecular mechanisms for conditions such as autism spectrum disorder and other disorders of childhood development, which are often caused by a combination of genetic variants affecting multiple genes and pathways.
Erik Holmlin, PhD, CEO of Bionano Genomics(BNGO) commented: “In the twenty years since the first human genome was sequenced, scientists have made countless discoveries about the function and mechanisms of the 20,000 human genes and the proteins they encode. Despite this progress, many thousands of genes are poorly characterized and their function unknown. At the same time, a large number of patients with genetic disease don’t receive a molecular diagnosis even after several genetic analyses because many of the identified variants are of unknown significance to the disease. Now, our Lineagen team can better interpret these VUS using our proprietary NeuroSCORE algorithm to diagnose more patients and provide more conclusive answers to families of patients with neurodevelopmental disease. When combined with the power of optical genome mapping with Saphyr, we believe neuroscientists could detect all structural variants genome wide and score them to make new discoveries. The NeuroSCORE publication is a great example of why Bionano acquired Lineagen last year – so that Lineagen’s extensive experience and understanding of genetic diseases, including neurodevelopmental disease, can accelerate advancement of applications for Saphyr.”
The publication is available on bioRxiv at https://www.biorxiv.org/content/10.1101/2021.02.04.429640v1
About Bionano Genomics(BNGO)
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential for NeuroSCORE to enable discovery of novel genes and improve diagnostic capabilities for patients with genetic disease, including neurodevelopment disease; our beliefs regarding the potential benefits of integrating NeuroSCORE with Bionano’s existing Saphyr technology; the contribution of expertise and resources from Lineagen to the advancement of current and future applications for our Saphyr system; and the execution of Bionano’s strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.(BNGO)
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
Image: Primary Logo
Source: Bionano Genomics(BNGO)
NEWS: Expanding space...16,607 additional square feet of office, manufacturing and warehousing space
http://app.quotemedia.com/data/downloadFiling?webmasterId=103779&ref=115652932&type=HTML
On February 15, 2021, Bionano Genomics, Inc. (the “Company”) entered into a Fourth Amendment to Lease Agreement (the “Lease Amendment”) with Irvine Eastgate Office I LLC (the “Landlord”), as successor-in-interest to The Irvine Company LLC (the “Original Landlord”), to amend the Lease Agreement, dated January 16, 2012, as amended, by and between the Company and the Original Landlord. Pursuant to the Lease Amendment, the Company leased an aggregate of 16,607 additional square feet of office, manufacturing and warehousing space in a building located at 9640 Towne Center Drive, San Diego, California 92121 (the “Expansion Space”). The term of the lease for the Expansion Space will commence on February 22, 2021 (the “Effective Date”) and will expire on December 31, 2025 (the “Term”). During the Term, the Company is required to remit base monthly rent of $44,008.55 from the Effective Date to December 31, 2021; $46,001.39 from January 1, 2022 to December 31, 2022; $47,994.23 from January 1, 2023 to December 31, 2023; $50,153.14 from January 1, 2024 to December 31, 2024; and $52,478.12 from January 1, 2025 to December 31, 2025. Notwithstanding the foregoing, the Company is entitled to an abatement of four full calendar months of base rent in the aggregate amount of $176,034.20 for the second, third, fourth and fifth full calendar months of the Term.
BNGO Stock: Why Bionano Genomics Shares Rallied 17% Today
https://investorplace.com/2021/02/bngo-stock-why-bionano-genomics-shares-rallied-17-today/
BNGO stock appears to have struck a chord with investors — here's why
By Chris MacDonald, InvestorPlace Contributor Feb 12, 2021, 4:10 pm EST
Bionano Genomics (NASDAQ:BNGO) is a stock that is on the move today. Shares closed out Friday higher by more than 17%. Why? Investors appear to be enticed by this company’s long-term prospects.
Additionally, a number of short-term catalysts have doubled this stock over the past month. Let’s take a look at what this biotech company does, and why it’s rallying hard today.
Business Model
Bionano is a genome analysis company. This company provides tools and services with its Saphyr system for genetic research and patient testing. Bionano’s Lineagen line of business also provides diagnostic testing for patients with Autism Spectrum Disorder (ASD), among the neurodevelopment disabilities. These technologies allow for the accelerated search for diagnostics and therapeutic options for these core disabilities. Additionally, Bionano’s products allow for more streamlined research into cytogenetics, the study of changes in chromosomes.
A recent InvestorPlace article describes the business model of Bionano quite aptly. In a nutshell, the company’s Saphyr system is gaining a lot of attention among investors. Indeed, there’s a tremendous amount of speculation this company could be on to something big.
Short-Term Catalysts Are Taking BNGO Stock Higher
BNGO stock has rallied a few times in recent days on news of bullish catalysts that have materialized. Among the most important investors should consider are the following:
Earlier in January, positive test results for the company’s Saphyr system were reported by Bionano. These results appear to be a key catalyst behind this stock’s parabolic rise this year.
This Saphyr system recently was approved for a pilot program by Canada’s largest diagnostic lab. The market appears to like the validation of one of Bionano’s core products.
The company announced it received an extension to maintain compliance with the Nasdaq Exchange. As with other stocks that have the risk of delisting weighing on expectations, it appears BNGO stock has assuaged these concerns. The removal of this anchor weighing on this stock seems to have added to BNGO stock’s existing momentum.
Retail investors have jumped on BNGO stock as a potential moonshot bet. Investor sentiment around stocks like BNGO with tremendous momentum continues to accelerate already impressive gains.
Bionano’s CEO recently announced a fireside chat with investors for next Thursday. This appears to be going over well with retail investors. Indeed, it seems investors may be more interested in companies that contend to be more open with their investment base. This is also a company doing something good for humanity, so BNGO stock looks like a win-win for everyone right now.
On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article.
4 Top Stock Trades for Tuesday: BNGO, MJ, NWL, CIIC,
Here are the top stock trades we’re watching for Tuesday morning
https://investorplace.com/2021/02/4-top-stock-trades-for-tuesday-mj-nwl-ciic-bngo/
By Bret Kenwell, InvestorPlace Contributor Feb 12, 2021, 5:28 pm EST
top stock trades - 4 Top Stock Trades for Tuesday: MJ, NWL, CIIC, BNGO
We’re getting a very tight trading range this week, with the S&P 500 keeping the damage limited but also not allowing much upside traction. Will stocks resolve higher or lower in the upcoming holiday-shortened week? We’ll know soon enough. With all of that in mind, let’s look at some top stock trades in the meantime.
Bionano Genomics (NASDAQ:BNGO) is ripping higher on Friday, finishing 17% higher on the day. The move thrust shares over $12.50 resistance and at least temporarily sent the stock to new highs.
The stock has been strong for several months, then gave us a sharp pull to the 10-day moving average — the first setup we like for a bounce. We got the initial bounce, but it was followed mostly by sideways consolidation, which is just fine.
Traders could have played the bounce and bailed during consolidation if they so chose. However, the stock continued to ride the 10-day moving average, which shows that bulls are engaged and accumulating on the dip.
When the stock went weekly-up over $12.70, traders were looking for a move back toward the $13.85 high. A few traders surely booked some profit into that zone. If they kept a partial position, they’re likely looking for a move up toward $15 and potentially up to the 161.8% extension near $16.50.
On the date of publication, Bret Kenwell did not have (either directly or indirectly) any positions in any of the securities mentioned in this article.
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell.
Bionano Genomics call volume above normal and directionally bullish (TheFlyOnTheWall)
THE FLY 11:45 AM ET 2/12/2021
Symbol Last Price Change
BNGO 13.29up +1.59 (+13.5897%)
QUOTES AS OF 11:55:34 AM ET 02/12/2021
Bullish option flow detected in Bionano Genomics(BNGO) with 46,321 calls trading, 2x expected, and implied vol increasing almost 8 points to 192.28%. Feb-21 13 calls and Feb-21 12 calls are the most active options, with total volume in those strikes near 16,900 contracts. The Put/Call Ratio is 0.14. Earnings are expected on March 4th
Bionano Genomics Has a Story That Investors Should Get Behind
Investors should be cautious about BNGO stock, but they can consider buying it
https://investorplace.com/2021/02/bngo-stock-is-compelling-story-stock/
By Chris Markoch Feb 12, 2021, 7:48 am EST
After a quick glance, it might be easy to write off Bionano Genomics (NASDAQ:BNGO) as another “meme stock.” After all, in late December the name was a penny stock and a fairly weak one at that. On Christmas Eve, BNGO stock closed at 71 cents per share. By New Year’s Eve, it was up to $3.08, and the cork blew off this stock in January.
Bionano has caught the attention of Robinhood traders. But that’s not why I’m recommending that investors exercise caution before diving into the shares. There are many examples of times when retail investors have gotten it right.
But, in a short amount of time, Bionano has flown really high. On the other hand, even though it might be ahead of the company’s outlook, BNGO stock gives everyone a great deal to root for.
Using Genetics to Fight Cancer, COVID-19, and More
Bionano Genomics works in the field of cytogenetics. According to the National Human Genome Research Institute, cytogenetics “is the branch of genetics that studies the structure of DNA within the cell nucleus.” It involves testing samples of tissue, blood, and bone marrow in laboratories to look for changes in chromosomes, including broken, missing, rearranged, or extra chromosomes.
BNGO stock has largely flown under the radar. But that changed recently because Bionano has a genome-imaging system, Saphyr, that is drawing attention from investors for a couple of specific reasons.
The first major event occurred in December. That’s when the tumor-testing platform of the company’s Saphyr system delivered positive clinical results. Researchers are using the Saphyr system to increase their understanding of the genome structures that make certain tumors so aggressive. By conducting such a study, researchers will be able to develop targeted therapies, better classify cancer subtypes, and make existing cancer treatments more efficient.
Then in January, the company released information from a study that identified key structural variants (SVs) which may provide researchers with a better understanding of why Covid-19 affects patients so differently. The senior author of the study, Ravindra Kolhe, MD, PhD, remarked that the Saphyr system had effectively mapped out large genomic variants that other methods had missed.
Erik Holmlin, PhD, CEO of Bionano Genomics, added: “…The results also demonstrate that even when a disease has already been studied extensively with sequencing, OGM with Saphyr has the potential to reveal significant insights not seen without it.”
The field of genetics is tantalizing for many reasons. I’ve always believed that one reason for that is that even to the “scientifically challenged” (including myself), the promise of genetics makes complete sense. We all have unique DNA. We often don’t recognize when our genetic code works to our benefit. However, we’re all too aware when something goes wrong.
The trading volume and volatility of BNGO stock have quieted down significantly. Bionano is scheduled to deliver its quarterly earnings report in March. It’s likely that investors do not expect new information to move the stock before then.
However, that gives them time to do due diligence. A long position in BNGO stock may be well-rewarded, but it won’t be without its ups and downs. And if you’re looking to trade the name, pay close attention to what analysts expect from the company’s upcoming earnings report.
Investors are betting on the promise of electric vehicles and cannabis and with good reason. But we should all be rooting for Bionano to deliver on its promise. The stock may undergo some volatility in the short-term. However, this is a company we can all get behind.
On the date of publication Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Chris Markoch is a freelance financial copywriter who has been covering the market for seven years. He has been writing for InvestorPlace since 2019.
Bionano Genomics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano’s Chief Executive Officer, is scheduled to participate in a fireside chat on Thursday, February 18, 2021 at 1:30 pm PST.
A live webcast of the presentation will be available to view on the Events page in the Investors section of Bionano’s website at https://ir.bionanogenomics.com/ and will be archived on Bionano’s website for 30 days following the event.
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s capabilities in comparison to and in conjunction with other genome analysis technologies, including in the comprehensive analysis of cancer genomes; the potential for Saphyr to reduce or eliminate sequential and confirmatory assays and expedite patient treatment; our expectations regarding the adoption of Saphyr as a clinical tool to replace traditional standard of care cytogenomic testing methods; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
Primary Logo
BioNano Genomics Is in a Perfect Bull-Bear Tug of War
https://investorplace.com/2021/02/bngo-stock-perfect-tug-of-war/
The BNGO stock price chart opens itself to dual interpretations
By Josh Enomoto, InvestorPlace Contributor
Feb 10, 2021, 1:32 pm EST
Before you blast me with what I’m about to say next, I’m not pointing fingers, just to be clear. However, the pharmaceutical and biotech industries demonstrated cynical capitalism at its finest. When the novel coronavirus first hit us, the crisis threatened to disrupt everything. Naturally, everyone that could transitioned to addressing SARS-CoV-2. You can add BioNano Genomics (NASDAQ:BNGO) and BNGO to this list.
To be honest, many of these biotech pivots had my eyes rolling. It just seemed to me that any medical solution for any medical condition – fungus, cancer, hair loss, you name it – was suddenly a viable platform for attacking the virus that causes Covid-19. You’ll forgive my skepticism as many of these so-called synergies didn’t appear logical or more importantly, viable.
However, there are certain investments where, even if the underlying motivation is more cynicism than science, the pivot makes sense. Fundamentally, this may be the case for BNGO stock. The underlying company has an exciting business unit called Saphyr System, which specializes in optical genome mapping that can identify structural variants of microorganisms.
Thus, outside the Covid-19 narrative, BNGO stock is a relevant play on the burgeoning field of cytogenetics – a branch of genetics “that studies the structure, function, and evolution of chromosomes.” Given the rise in cases involving genetic disorders, biotech firms like BioNano survived or thrived from speculation that cytogenetics will spark next-generation medical solutions.
While we may be a bit removed from addressing genetic ailments, BioNano received huge interest recently because its Saphyr System produced encouraging research results regarding the nuanced workings of the SARS-CoV-2 virus. As BioNano stated last month in its press release, Saphyr “may provide key insights into the pathogenesis of COVID-19 and outcomes in patients who become severely ill.”
The Allure and Danger of BNGO Stock
Prior to the Super Bowl, many worried that various parties celebrating the big game may lead to superspreader events. Because there’s a lag between infections and the reporting of them, we may not know for several days whether this materializes. If so, there’s another cynical element to consider if you’re bullish on BNGO stock.
To be fair, though, Covid-19 cases have sharply deteriorated over the last few weeks. According to the latest read from the Centers for Disease Control and Prevention, daily infections dipped into five-digit territory on Feb. 7, with the trend reassuringly negative. If this continues, BNGO stock might appear to lose some of its newfound relevancy.
But it’s important to note that BioNano wasn’t necessarily banking on the pandemic. Instead, the coronavirus was a backdrop to prove that Saphyr could actually deliver practical solutions and that the system was just a pretty lab queen.
Basically, Saphyr is the Tom Brady of the cytogenetics sector, while Covid-19 is the Tampa Bay Buccaneers. By moving to a new team and winning a championship, Brady proved he’s no longer a system quarterback. It’s the same concept with Saphyr.
But is BNGO stock the Tom Brady of investments? Here’s where the story takes a twist. According to my InvestorPlace colleague Chris Tyler, a technical setup – a “symmetrical triangle pattern,” as he put it – suggests a possible upside move. He has some specific caveats that you should read about before initiating a position.
I’m partial to his argument about triangular patterns – I believe most technical analysts call it a pennant formation – because I used it myself for identifying a bullish rally in DraftKings (NASDAQ:DKNG).
However, you should also note that in the year-to-date when BNGO stock gained almost 64%, volume has been conspicuously declining. Typically, technical analysts regard a rising price, falling volume combo to be bearish.
Which Interpretation Do You Trust?
When it comes to technical analysis, I’d say I know a fair amount, although I always learn more from experts in the field. Chris Tyler is one such expert. Just from an education and credibility standpoint, if you had to trust somebody’s technical interpretation, I’d go with Tyler.
Don’t worry about making me feel bad because I’d choose Tyler over me any day.
However, there is a part of me that says, hold on now! What’s interesting about my DKNG bull call was that volume confirmed the pennant formation. With BNGO, volume is only partially confirming it – as in prior to January 2021. In this year, volume is moving against the direction of BNGO.
So, where does that leave us? I’d say that if you don’t want the regret of missing out on BioNano, go ahead and put a modest amount of speculation money toward BNGO stock. But do keep the powder keg dry because this technical setup may be flawed.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
Bionano Genomics call volume above normal and directionally bullish (TheFlyOnTheWall)
THE FLY 10:25 AM ET 2/11/2021
Symbol Last Price Change
BNGO 11.4up +0.02 (+0.1757%)
QUOTES AS OF 12:35:22 PM ET 02/11/2021
Bullish option flow detected in Bionano Genomics(BNGO) with 11,835 calls trading, 1.1x expected, and implied vol increasing almost 3 points to 183.00%. Feb-21 13 calls and Feb-21 12 calls are the most active options, with total volume in those strikes near 4,700 contracts. The Put/Call Ratio is 0.10. Earnings are expected on March 4th
Method for Solid Tumor Analysis with Saphyr Published by Penn State Institute for Personalized Medicine, Opening Largest Oncology Market to Optical Genome MappingPublication demonstrates that Saphyr can be powerful and easy to use for solid tumor analysis in cancer research and clinical testing
GLOBENEWSWIRE 8:00 AM ET 2/11/2021
Symbol Last Price Change
BNGO 11.38down 0 (0%)
QUOTES AS OF 04:00:01 PM ET 02/10/2021
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.(BNGO) , announced the publication of a method for using optical genome mapping (OGM) to identify structural variants (SVs) that drive cancer in a wide variety of solid tumor samples. The study, led by Dr. James Broach, Chair of the Department of Biochemistry and Molecular Biology and Director of the Penn State Institute for Personalized Medicine, used the Saphyr® system for OGM to characterize structural variation in twenty solid tumor samples from cancer patients. The study showed that Bionano’s workflow can routinely isolate ultra-high molecular weight DNA from solid tumors, that its software is able to identify the cancer-specific variants in the tumor, even when they are present at low abundance in highly complex tumors, and that in every sample OGM found variants affecting important cancer genes. OGM with Saphyr has been previously validated in constitutional genetic diseases from blood samples and hematologic malignancies from blood and bone marrow aspirates. The current study demonstrates that OGM with Saphyr is also simple to use with solid tumors, the most common sample for cancer research and clinical testing.
Using Bionano’s SP Tissue and Tumor DNA Isolation Kit, Dr. Broach’s team successfully extracted ultra-high molecular weight DNA from a wide variety of human solid tumors including breast, colon, liver, brain, bladder, kidney, lung, ovary, prostate and thyroid cancer tissue. Every tumor sample carried at least one SV affecting important tumor-suppressor or oncogenes and most contained multiple variants. Several of the genes identified by OGM offer the opportunity for targeted therapies.
Jim Broach, PhD, commented: “Oncologists studying liquid tumors, such as leukemia, have had the ability to visualize somatic SVs across the entire tumor genome through karyotyping. This tool has afforded enormous benefits for prognosis and treatment selection, resulting in significant and steadily improving outcomes for such patients. Solid tumors cannot be analyzed by karyotyping, meaning that oncologists dealing with those tumors - breast, lung, prostate, brain, etc. - have not had that tool in their diagnostic arsenal. Our results with Bionano’s OGM technology demonstrate the feasibility not only of obtaining the same global view of somatic SVs across the entire solid tumor genome but also of doing so with a 10,000 times greater resolution than that afforded by karyotyping. We anticipate that, like the recent history with karyotyping and liquid tumors, OGM will yield unprecedented insights into solid tumor diagnosis and treatment with the potential for the same steady increase in improved patient outcomes.”
Erik Holmlin, PhD, CEO of Bionano Genomics(BNGO) commented: “The ability of an oncologist to prescribe the optimal treatment for a cancer patient depends on their ability to fully characterize all variants found in the patient’s tumor. Studies from around the world had already shown that Saphyr detects SVs comprehensively in a variety of leukemias. Dr. Broach’s work now demonstrates that Saphyr is uniquely capable of identifying clinically important SVs in solid tumor samples as well and that it does so with a simple, automated analysis workflow that doesn’t require complex bioinformatic analysis. By adding solid tumors analysis to that of leukemias for both cancer research and clinical testing, the largest market in oncology becomes accessible to Bionano.”
The publication is available on medRxiv at https://www.medrxiv.org/content/10.1101/2021.02.04.21250683v1
About Bionano Genomics(BNGO)
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s capabilities in comparison to and in conjunction with other genome analysis technologies, including in the comprehensive analysis of cancer genomes; the potential for Saphyr to reduce or eliminate sequential and confirmatory assays and expedite patient treatment; our expectations regarding the adoption of Saphyr as a clinical tool to replace traditional standard of care cytogenomic testing methods; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.(BNGO)
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
Image: Primary Logo
Source: Bionano Genomics(BNGO)
Bionano Genomics Saphyr System Being Piloted By University Health Network
DOW JONES & COMPANY, INC. 8:47 AM ET 2/9/2021
Symbol Last Price Change
BNGO 11.65up 0 (0%)
QUOTES AS OF 04:00:00 PM ET 02/08/2021
Bionano Genomics Inc. (BNGO) said its Saphyr system is being piloted by the University Health Network's Laboratory Medicine Program in Toronto.
The Laboratory Medicine Program is the largest hospital diagnostic laboratory in Canada and one of the largest in the world, performing 25 million tests per year and serving 1,300 patients per day.
The company said UHN's Cancer Cytogenetics Laboratory plans to use the Bionano Saphyr system to test its ability to streamline cancer diagnostic techniques, improve detection of abnormalities and reduce complexity and costs.
The lab said it hopes to use the power of optical genome mapping by developing new Saphyr-based assays intended to resolve diagnostic questions that are challenging with existing standard of care tools.
Bionano Genomics (BNGO) shares were up 8% to $12.51 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
02-09-210847ET
Largest Hospital Diagnostic Lab in Canada Pilots Bionano’s Saphyr; Seeking to Convert 30-Year-Old Workflow Based on Multiple Technologies Into a Single, High-Resolution Assay to Transform Cancer Diagnosis
GLOBENEWSWIRE 8:00 AM ET 2/9/2021
Symbol Last Price Change
BNGO 11.65up 0 (0%)
QUOTES AS OF 04:00:00 PM ET 02/08/2021
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.(BNGO) , announced today that its Saphyr system is being piloted by the University Health Network's (UHN) Laboratory Medicine Program (LMP) in Toronto. The LMP is the largest hospital diagnostic laboratory in Canada and one of the largest in the world, performing 25 million tests per year and serving 1,300 patients per day. UHN’s Cancer Cytogenetics Laboratory led by Dr. Adam Smith plans to use the Bionano Saphyr system to test its ability to streamline cancer diagnostic techniques, improve detection of abnormalities and reduce complexity and costs.
Dr. Adam Smith commented: “The hope is to leverage the unique power of optical genome mapping (OGM) by developing new Saphyr-based assays intended to resolve diagnostic questions that are challenging with existing standard of care tools. Cytogenetics, and specifically G-banded karyotyping, is a core technique for looking at chromosomal changes in cancer patients and has been a core technique of cytogenetics laboratories for over 30 years. Karyotyping has provided a cost-effective means to assess chromosomal changes at the genome level, but it is labor intensive and has limited resolution to identify specific rearrangements. While other techniques such as Fluorescence In Situ Hybridization (FISH) have supplemented karyotyping, FISH is a targeted assay requiring continued validations and workloads for new and emerging cancer biomarkers. New technologies, such as OGM, may represent a better alternative and increase the precision of detecting chromosomal changes in cancer. This could lead to the clinical reality of a single assay, high-resolution analysis across the entire genome."
Erik Holmlin, PhD, CEO of Bionano Genomics(BNGO) commented: “It is gratifying to see increasing adoption of Saphyr as the evidence continues to mount showing how Saphyr can consolidate multiple antiquated techniques into a single, streamlined approach for cytogenomic analysis. This pilot by Canada’s largest hospital diagnostic laboratory is a significant milestone for us as we seek to make OGM with Saphyr a cornerstone of efforts to improve cancer diagnosis and discover new medicines. We thank Dr. Smith and his colleagues for their commitment to us and we are impressed by their innovative drive.”
About Bionano Genomics(BNGO)
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the strategic plans of UHN’s Cancer Cytogenetics Laboratory, including its plans to develop Saphyr-based assays; Saphyr’s capabilities in comparison to and in conjunction with other genome analysis technologies, including in the comprehensive analysis of cancer genomes; the potential for Saphyr to streamline cancer diagnostic techniques, including its abilities to reduce or eliminate sequential and confirmatory assays, improve detection of abnormalities, reduce complexity and costs and help facilitate the discovery of new treatments; our expectations regarding the adoption of Saphyr as a clinical tool to replace traditional standard of care cytogenomic testing methods; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.(BNGO)
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
Image: Primary Logo
Source: Bionano Genomics(BNGO)
Gastric RE: being shorted....Ethics, integrity, Magnamity, Justice, Compassion, Responsibility, Vision...
One might think that betting against, being short, a stock that may bring so much to so many would bother ones conscience.
Some things should not be about the precious dollar.
Life saving, life changing technology for those who suffer with everything from mental illness to cancer is not a company that should be squashed.
Perhaps going long and supporting the vision would make one more $$ than the possibility of this stock going back down to the $.85 range?
This is game changing.
Eli, Yes, we met at one of the earlier shareholders meetings in NYC so many years ago.
I have looked at some of your holdings. Some too early for me. I will look into rest as time permits.
I no longer share my buys with friends or family as I have learned that it is a loose, loose. You really have to keep them updated forever on your buys and sells. Too much responsibility. :)
This one is a bit different as although it has alread had a great rise, it still haa great possibilities to do that again. Cathie Wood states it to be the year of Genomics.
Cathie is well aware of BNGO. If she hops on it will just move that much faster. However, BNGO will move on its own with or without ARK.
Today I added some more warrents, BNGOW. They dropped below $6 and "should" move in parity soon with a bettter ratio of profit based on the lower cost basis.
While this is heavily shorted and may seem expensive and a worthy target for the shorts, they may lack visions and they only have limited upside ($11), while I think there is great vision for this company and a much larger upside.
My daughter is also in the Psyciatric field and liked the possibilities of theraputics based on findings.
I guess time will tell who is correct on this one. :)
All the best for a grand day!
VH
Analyst Actions: Oppenheimer Adjusts Bionano Genomics' PT to $15 From $1.50, Citing Balance Sheet Expansion, Potential of $100 Genome; Outperform Rating Kept
MT NEWSWIRES 10:33 AM ET 2/8/2021
10:33 AM EST, 02/08/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Price: 11.02, Change: -0.03, Percent Change: -0.27
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited
This company is heavily shorted.
https://nakedshortreport.com/company/BNGO
While we can only look at them for time to time buying opportunity at this point.
At some time in the future they will be helpful with momentum. :)
A warmhearted hello to all the gang who stop by.
Wavxalmiman,
I keep in contact with Weby and plan to meet him & Ellen in NY again post covid. I have seen Trippi on the news occasionally over the years.
I came back to IHUB to see if any interesting DD on a company I quite liked. It was Sureal as I saw JessseLivermore talking about it and ClayTrader doing his famous charts on the stock. It was like a blast from the past. So I had to stop by here and was surprised that there were still posts.
RE: Snackman Stock
I prefer to buy companies that are closer to the product success. I'm too old to have patience. :)
I don't trade much, mainly lots & lots of research then buy and hold future good quality companies. After 20 years I came back. I could go on and on about the stock I posted yesterday about. The mapping of mental illnesses, cancer ect. and comparisons to other genome mapping. I suggest everyone do DD rather than me hype. If still into doing DD the Genomics company ticker BNGO is quite attractive in their abilities. It has been down past few days so, chart may not look spectacular. (Disclosure: I own too much and I just continue to buy weekly and all recent dips into the 10's. Sadly or not sadly, it is very heavily shorted) Nothing to immediatly hype about price, just stellar possibilities if you do the DD. If want hype, JessieLivermore posts it will be " the stock of the decade" which when I read that board yesterday, kinda made me feel more comfy with my research in my little bubble. LOL Worth a look while price is depressed. Not a suggestion to buy as I do not know your situation. All my other companies are slightly less exciting regarding upward possibilities.
I still love to research and enjoy life even while staying safe in a pandemic.
I wish all the best for you all for a healthy & Prosperous 2021!
Have a grand day!
VH
I just stopped by to see if this board was still around.
A few minutes ago, on another board, I posted on IHUB for the first time in almost 20 years! I had to come over here to see if anyone still around and saw your post wondering if any of the old gang were around.
I'm still around and loving life.
I hope you are all well!
Yes, Exciting times in the sciences.
I wish you all the best for a grand 2021!
VH
RE: "I am calling this stock of the decade.."
I might have to agree. This company is quite intriguing!
I have not posted on these boards for literally 20 years, but I will come out of the woodwork for the possibilities of this one!
It is mind boggling the posibilities going forward for everything from inherited Mental illnesses to Cancer discoveries and treatments.
Disclosure: My son has been buying since $.85 and me regularly $2.70-$12.35 so far... I no longer trade a lot, but do deep research my buy and holds constantly. I have read and listened to just about everything I can find on $BNGO. I feel this is a buy and put in your drawer stock. Cathie Woods claims this is the year of Genomics and whether she purchases this stock or not, this company has the capacity to add so many possibilities in medical discoveries and treatments. This is not an endorsement to buy this security. My opinion does not matter. Please do your DD as it relates to your own risks.
I look forward to the future findings this company releases.
Meanwhile, have a grand 2021!
Would anyone have any insight as to why the Warrents BNGOW are not trading in parady with the BNGO Stock price?
Blue fin . . . . Why?
Because they can!
Barge, RE:MM moving the posts
I cannot even tell you how often this has happened to me. So frustrating! I usually waited till the shares were offered in total and STILL not gotten them. They suddenly disappear filling a partial and moving the price .001 above my offer. (which is not right!)
What is suppose to happen is that you would get all that was offered at the price offered and then then the MM you buy through does not have to go to the MM's for the next fraction of a cent up...they only have to offer out of their own stock after it goes above the main offered price. So while other mm's may have offers between the listed offer and your offer, your MM does not have to give it to you. Thus the price usually pops right back down after such a purchase if you are totally filled.
With your deal...They just dd not want to sell any shares at all. (probably too short right now... :)Friday should be interesting!
While this is how the game is played, and we must just suck it up & buy where offered. We have to wait for the days when volume comes in and the traders come back to this stock. no matter how we "hate" the "Traders" they do bring a bit of excitement.
First things first...the chart has to look enticing! WAVX has got to add a good $.27 at this point till you past some basic resistance before we get a glance. (or some decent PR's)
Take Care!
VH
Cisco and Juniper Networks Take Promoter and Board of Directors Positions with the Trusted Computing Group (TCG)
Leading Networking Infrastructure Providers to Create and Promote Trusted and Secure Data, Systems and Connections
http://www.marketwatch.com/story/cisco-and-juniper-networks-take-promoter-and-board-of-directors-positions-with-the-trusted-computing-group-tcg-2012-05-23?siteid=nbkh
PORTLAND, Ore., May 23, 2012 (BUSINESS WIRE) -- Cisco has joined the Trusted Computing Group (TCG), an organization that develops open international industry standards, as a Promoter member to serve on its board and help drive the evolution of the group's successful specifications for trusted systems. TCG also announced that Juniper Networks, a current TCG member, now will participate in TCG as a Promoter member with a position on the board of directors.
Cisco and Juniper Networks will work closely with board members from Advanced Micro Devices; Fujitsu Ltd.; Hewlett-Packard; IBM; Infineon Technologies AG; Intel Corporation; Lenovo Holdings Ltd.; Microsoft; and Wave Systems. Elected Contributor board members currently include representatives from Dell and Nokia.
"TCG's specifications, embedded into hundreds of millions of PCs, servers, storage systems and networking devices, defend enterprises and users daily against attacks, theft, malware and data loss," commented Joerg Borchert, TCG president and chairman and Infineon vice president, Chip Card & Security ICs, Infineon Technologies North America Corporation. "With the expertise of two of the world's leading networking infrastructure companies, TCG's board and work groups can continue to evolve our security standards to protect data, systems and connectivity for wired and wireless environments."
TCG has created many specifications based on the root-of-trust concept, including the widely implemented Trusted Platform Module (TPM) included in more than 500 million PCs, servers and other platforms; self-encrypting drives (SEDs) available from most storage vendors; and Trusted Network Connect (TNC) for network security, included in products from dozens of vendors.
Through development of open industry standard specifications, the Trusted Computing Group (TCG) enables a safer computing environment for the entire platform and in remote locations. Trusted Computing is useful for protecting business-critical system and data, providing secure verification methods, reinforcing user ID protection, and ensuring machine ID and network authenticity. Trusted Computing is highly reliable, and organizations utilizing widely available internal hardware and applications can install or own it at a lower cost. Furthermore, TCG technology conforms to regulations for reliable hardware. For details regarding the abovementioned information, specifications developed by TCG, work groups, etc., refer to the Trusted Computing Group website ( www.trustedcomputinggroup.org ). Follow TCG on Twitter and LinkedIn.
All listed brand names and trademarks belong to their respective owners.
SOURCE: Trusted Computing Group
Scrambls Wins 2012 National Child Safety Award
Scrambls Gives Users Control of their Personal Information on Social Networks
http://www.marketwatch.com/story/scrambls-wins-2012-national-child-safety-award-2012-05-09?siteid=nbkh
ANAHEIM, Calif., May 09, 2012 (BUSINESS WIRE) -- The Child Safety Network (CSN), America's leading child safety organization since 1989, has chosen scrambls as the recipient of its 2012 National Child Safety Award. Scrambls is a free service that empowers users to control and protect messages posted to the web and social networking sites. With scrambls, parents and their children gain lasting control of every tweet, blog post or status update.
"Social media sites contain a treasure trove of personal information that, in the wrong hands, can put children in jeopardy--whether through identity theft, cyber bullying or even the act of luring youngsters into threatening situations," said Ward E. Leber, CEO of the Child Safety Network. "Scrambls gives families the controls they need to make social networking safer, providing direct management of who kids communicate with and all of the content that they share--working directly on the sites they already use."
Scrambls also earned the Safe Family Seal of Approval, which lets parents and schools know that the world's leading child advocates and child safety experts have reviewed, tested and agreed that scrambls can help protect your family.
Scrambls is a secure web browser plug-in that encodes selected content with the flip of a switch--from e-mails and tweets to posts on any website. You choose who may access (i.e. read) your information, selecting individuals or sharing with a group. Friends just need to add scrambls to their own browser and messages will look the same as usual for them. Anyone else that was not approved to read the post will see only scrambld text. Not even the providers of the social media sites can access your personal messages. With the click of a mouse, you can post messages for everyone to read, or protect it so, for example, "only Mom, Grandma and I can read." You can even retract (delete) messages, or change the permissions for who can read it after the message has been published.
Scrambls provides families with the ability to share content on their favorite sites and yet retain full control of that data. Children and young adults can now take responsibility to protect their reputation online, so messages won't come back to haunt them in the future--particularly important when applying for college or jobs.
Scrambls is available world-wide at www.scrambls.com and is free for personal use.
"We applaud the work of the Child Safety Network and are honored to receive the National Child Safety Award," commented Steven Sprague, co-creator of scrambls and CEO of Wave Systems, the security company that developed the service. "The power of scrambls is that it can protect children online on many different levels. Even beyond the realm of child safety, there are compelling reasons why you'd want to maintain control over your personal content. Your political positions or social conversations at age seventeen may not go over well when you run for president. The communications among your classmates for projects and trips don't need to be read by everyone on your dad's friends list. Social media provides important new ways for collaboration, and scrambls will both protect and enable those interactions."
The award comes during the 113th California State PTA Annual Convention where CSN presents its prestigious national awards each year. A formal presentation of the award will take place at the culmination of this year's convention. Steven Sprague, CEO of Wave Systems will receive the award on Saturday, May 12 at 11:00 a.m.
About Scrambls
Scrambls is a service developed by Wave Systems Corp. WAVX +6.25% that makes online sharing simple and safe. All you need is the scrambls plug-in added to your browser toolbar. You can make any post private with just one click, even if you're publishing to different groups of contacts spread across multiple social networks. Scrambls lets you decide what the privacy policy will be for each post that you share. Scrambls makes online sharing smarter, with control over what you are sharing and whom you are sharing it with.
About Child Safety Network (CSN):
Since 1989, CSN has been making America a safer place for children to live. Our mission is to reduce the likelihood of children becoming victims of abuse, abduction, exploitation, and injury. We accomplish our mission by developing and implementing safety education programs on a national basis. CSN's work is endorsed by over 300 U.S. Representatives, 250 major celebrities, the current and past four presidential administrations, law enforcement, educators, PTA volunteers and numerous local, state and national civic organizations. Please visit: www.csn.org .
SOURCE: Child Safety Network
CSN
Ward Leber, 800-906-6901
media@csn.org
Copyright Business Wire 2012
If it’s private, make mine Scrambl’d
http://bostonherald.com/business/technology/general/view/20220502if_its_private_make_mine_scrambld_plug-in_would_protect_social_media_posts
Plug-in would protect social media posts
Jessica Van Sack By Jessica Van Sack / Booting Up
Wednesday, May 2, 2012 -
To understand the latest technological venture by Wave Systems Corp. CEO Steve Sprague, you should know that his great-great-grandfather Frank J. Sprague was the “Father of Electric Traction,” having invented the first way to run electricity to trolleys in 1880 — and a lifetime of his notes now sit in the New York Public Library.
Steve Sprague believes that if his great-great-grandfather were around today, his notes would likely be a series of digital outputs scattered throughout the Twitterverse and Facebook, content that he would not own and that would be subject to the privacy whims of Mark Zuckerberg and others.
Wave, a digital security company based in Lee, has pioneered a new product called Scrambls, an Internet plug-in that supercedes the privacy rules of social media sites. Set to be unveiled today after months of testing, Scrambls allows the user to encrypt individual content so that even Facebook can’t view what you post on your Facebook wall.
The upshot is you don’t have to delete your entire Facebook or Twitter account to scrub the Web of every youthful indiscretion that might linger in far-off corners of the Internet. It can remain online, but visible only to you.
Sprague said Scrambls will put an end to a recent trend of paranoid users who delete their entire account once it’s time to graduate from college and apply to a real-world job.
“That’s really a false choice,” he said.
Scrambls works by encrypting your posts before delivering them to the Web. Only the user owns the code, or “key” to unlock the encryption, and can set the policy for whom and when to make the “keys” available.
So, if you post a comment on a friend’s Facebook or Twitter account and only want it visible to that friend, for the rest of the world it will appear like a garbled wingdings font. Only you and the friend will be able to view it.
Because Scrambls is an Internet plug-in, it doesn’t matter what the privacy policy is on the site you’re using. You’ll control who sees what, and be able to choose from various customizable groups.
Users can also scramble part of a post, like those containing a phone number or other personal information. And settings allow for a time expiration on public posts, scrambling them after a set period of time so only you can see them.
“This enables me to have a very simple mechanism to protect and to have persistent control over my posts,” Sprague said.
Sprague envisions a wider application for his newest project: the ability to expand what we do on social media sites. Take Yammer.com, for instance, the social media site for corporations. With Scrambls, Sprague believes companies could use Yammer to conduct business without fear that confidential information will leak out.
“Today my doctor’s office sends me mail when I get test results,” Sprague said. “Why not send me a Twitter feed?”
And for the modern-day Frank J. Spragues of the world, that means a lifetime of Facebook musings could remain in the possession of those who wrote them, a novel concept.